Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.10. | Galera Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
06.09. | NSE - Galera Therapeutics, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 4 | SEC Filings | ||
04.09. | Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition ... | 60 | GlobeNewswire (Europe) | NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of Liberty Resources Acquisition Corp. Liberty Resources... ► Artikel lesen | |
04.09. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
14.08. | Galera Therapeutics plans to dissolve and liquidate assets | 5 | Investing.com | ||
14.08. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.08. | Galera Therapeutics: Galera Announces Board Approval of Complete Liquidation and Dissolution | 132 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary... ► Artikel lesen | |
08.08. | Galera Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
03.06. | Why Galera Therapeutics (GRTX) Stock Is Nosediving | 12 | Benzinga.com | ||
03.06. | Galera Therapeutics, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
13.05. | Galera Therapeutics GAAP EPS of -$0.08 | 2 | Seeking Alpha | ||
13.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
13.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Galera Therapeutics: Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates | 213 | GlobeNewswire (Europe) | MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics... ► Artikel lesen | |
03.05. | Galera Therapeutics: Galera Adopts Limited Duration Stockholder Rights Agreement | 256 | GlobeNewswire (Europe) | MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the... ► Artikel lesen | |
28.03. | Galera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates | 231 | GlobeNewswire (Europe) | MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have... ► Artikel lesen | |
14.11.23 | Galera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates | 370 | GlobeNewswire (Europe) | FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 8,100 | +13,37 % | Evotec Aktie: Wochen der Wahrheit? | Bei der Evotec Aktie haben am Donnerstag und Freitag zum einen Gewinnmitnahmen nach dem jüngsten Kursanstieg das Bild geprägt. Aber - zumindest am Donnerstag - blieben zudem Rückkäufe der Evotec Aktie... ► Artikel lesen | |
EPIGENOMICS | 1,300 | +44,44 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
CORE ONE LABS | 0,079 | -100,00 % | XFRA LD6: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCORE ONE LABS INC.... ► Artikel lesen | |
CRISPR THERAPEUTICS | 46,700 | 0,00 % | Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers | ||
MAINZ BIOMED | 0,206 | -6,38 % | BRISANTE Meldung setzt Mainz Biomed Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
TREVENA | 0,153 | 0,00 % | Trevena, Inc.: Trevena Announces Receipt of Nasdaq Delisting Notification | CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,428 | +12,34 % | Defence Therapeutics Inc.: Defence Therapeutics Completes 1st Tranche of Financing | Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
CENTOGENE | 0,185 | 0,00 % | Centogene N.V. - 6-K, Report of foreign issuer | ||
GALAPAGOS NV | 24,480 | -0,97 % | Galapagos NV: Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update | We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing... ► Artikel lesen | |
GINKGO BIOWORKS | 6,950 | -2,80 % | Lesaffre strengthens its Research, Development & Innovation (RD&I) with the acquisition of Altar, a company owned by Ginkgo Bioworks | MARCQ-EN-BARŒUL, France, Oct. 7, 2024 /PRNewswire/ -- Lesaffre, a key global player in the field of fermentation and microorganisms, announces the acquisition of Altar, a French start-up... ► Artikel lesen | |
NOVOCURE | 15,010 | +0,54 % | Novocure meldet Finanzergebnisse des dritten Quartals 2024 | Quartalsnettoumsatz von 155 Millionen USD, Steigerung von 22 gegenüber dem Vorjahr, mit rekordverdächtigen 4.113 aktiven Patienten in Therapie zum 30. September 2024 FDA genehmigt Optune Lua... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 1,840 | -1,60 % | Cellectar Biosciences regains compliance with Nasdaq | ||
SENSEI BIOTHERAPEUTICS | 0,470 | +2,17 % | Sensei Biotherapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 6,665 | +3,57 % | Peering Into Recursion Pharmaceuticals' Recent Short Interest | ||
COHERUS | 0,617 | -7,55 % | Coherus BioSciences Aktie: Verstärkter Wettbewerbsdruck spürbar | Coherus BioSciences, ein auf Biosimilars und Immunonkologie spezialisiertes Unternehmen, steht derzeit vor erheblichen Herausforderungen. Die Aktie des in Redwood City ansässigen Unternehmens verzeichnete... ► Artikel lesen |